Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should Investors Buy the Dip in Charles River Laboratories (CRL) Stock?

Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.

In the said letter, Brown Advisory highlighted a few stocks and Charles River Laboratories International Inc. (NYSE:CRL) is one of them. Charles River Laboratories International Inc. (NYSE:CRL) is a clinical laboratory company. Year-to-date, Charles River Laboratories International Inc. (NYSE:CRL) stock gained 28.3% and on July 30th it had a closing price of $201.31. Here is what Brown Advisory said:

“Following a steep sell-off in March, Charles River Laboratories stock experienced a robust rebound as its focus on pre-clinical research activities proved more resilient than its clinical stage peers and market expectations. Specifically, discovery and safety assessment work for biotech companies remained strong, while the company experienced new wins related to the search for a COVID-19 vaccine.”

Easiest Md/PhD Programs to Get Into

Pressmaster/Shutterstock.com

In April, we had published an article revealing that Horizon Kinetics investment firm is bullish on Charles River Laboratories International Inc. (NYSE:CRL) stock. The firm belives that the company is into a high-quality business and is anticipating huge growth going forward.

In Q1 2020, the number of bullish hedge fund positions on Charles River Laboratories International Inc. (NYSE:CRL)  stock increased by about 13% from the previous quarter (see the chart here), so a number of other hedge fund managers seem to agree with CRL’s growth potential. Our calculations showed that Charles River Laboratories International Inc. (NYSE:CRL)  isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. Cannabis stocks are roaring back in 2020, so we are checking out this under-the-radar stock. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.